ACARIZAX® PRODUCT INFORMATION
AUST R 250392

NAME OF THE MEDICINE

ACARIZAX® 12 SQ-HDM oral lyophilisate.

DESCRIPTION

ACARIZAX® is allergy immunotherapy.

ACARIZAX® oral lyophilisate tablets contain 12 SQ-HDM standardised allergen extract from the house dust mites (HDM) Dermatophagoides pteronyssinus and Dermatophagoides farinae.

The unit SQ-HDM has been defined to measure the potency of ACARIZAX® and is based on a standardised amount of allergens from each species. Each tablet contains 6 SQ-HDM of D. pteronyssinus and 6 SQ-HDM D. farinae for a total of 12 SQ-HDM.

ACARIZAX® oral lyophilisate tablets 12 SQ-HDM also contain gelatin (fish), mannitol and sodium hydroxide.

PHARMACOLOGY

Pharmacodynamics
Pharmacotherapeutic group: Allergen extracts, house dust mite.

ATC Code: V01AA03

ACARIZAX® is allergy immunotherapy. Allergy immunotherapy with allergen products is the repeated administration of allergens to allergic individuals with the purpose of modifying the immunological response to allergen to provide sustained underlying protection during subsequent allergen exposure. The immune system is the target for the pharmacodynamic effect of allergy immunotherapy, but the complete and exact mechanism of action is not fully understood.

ACARIZAX® is for the treatment of patients with specific IgE-mediated allergy symptoms induced by HDMs such as allergic rhinitis and/or allergic asthma. Treatment with ACARIZAX® has been shown to induce a systemic antibody response with an increase in HDM-specific IgG₄ that is likely to compete with IgE in the binding of HDM allergens. This effect is observed after 4 weeks of treatment.

ACARIZAX® works by modifying the immune response to HDM (D. pteronyssinus and D. farinae) allergens and provides specific desensitization. Clinical effect during treatment has been demonstrated for both upper and lower airways (see CLINICAL TRIALS). The underlying protection provided by ACARIZAX® leads to improvement
in disease control and improved quality of life demonstrated through symptom relief, reduced need for other medications and a reduced risk for exacerbation.

Pharmacokinetics
No clinical studies investigating the pharmacokinetic profile and metabolism of ACARIZAX® have been conducted. The effect of allergy immunotherapy is mediated through immunological mechanisms, and there is limited information available on the pharmacokinetic properties.

The active molecules of an allergen extract are composed primarily of proteins. For sublingually administered allergy immunotherapy (SLIT) products, studies have shown that no passive absorption of the allergen through the oral mucosa occurs. Evidence points towards the allergen being taken up through the oral mucosa by dendritic cells, in particular Langerhans cells. Allergen which is not absorbed in this manner is expected to be hydrolysed to amino acids and small polypeptides in the lumen of the gastrointestinal tract.

CLINICAL TRIALS

Allergic asthma
The efficacy and safety of ACARIZAX® in adults with partly controlled HDM allergic asthma despite daily use of inhaled corticosteroid (ICS) has been investigated in a Phase III randomised, double-blind, placebo-controlled, parallel-group, multicentre study (MT-04, MITRA)(n=834).

This trial comprised 2 phases. In the first phase (treatment maintenance), subjects were randomised to receive ACARIZAX® 12 SQ-HDM, 6 SQ-HDM or placebo once daily in addition to inhaled corticosteroids (ICS; corresponding to 400-1200 mcg budesonide) and short acting beta agonists (SABA; salbutamol 200 mcg/dose). The duration of the treatment maintenance period was 7-12 months (this varied as efficacy measurements were initiated outside of major pollen seasons to minimise confounding from other allergies). The second phase (ICS reduction/withdrawal) ran for a total of 6 months. Subjects continued to take ACARIZAX® 12 SQ-HDM, 6 SQ-HDM or placebo once daily throughout the ICS reduction/withdrawal period. In the first 3 months of the ICS reduction/withdrawal period, each subject’s ICS dose was reduced by 50%, and in the last 3 months ICS was withdrawn completely. Use of SABA was permitted throughout the ICS reduction/withdrawal period if needed.

The primary endpoint was the time to the first moderate or severe asthma exacerbation during the reduction/withdrawal period. The definitions of moderate and severe asthma exacerbations are provided in Table 1.

The results for the primary endpoint are summarised in Table 2. Both ACARIZAX® 12 and 6 SQ-HDM demonstrated statistical significance compared to placebo for time to first asthma exacerbation (Table 2). The results for ACARIZAX® 12 SQ-HDM also met the pre-specified criterion for clinical relevance compared to placebo (i.e. HR ≤ 0.70). See also Figure 1.
Table 1. Definitions of moderate and severe asthma exacerbations (clinical trial MT-04)

<table>
<thead>
<tr>
<th>Ashma exacerbation</th>
<th>Definition</th>
</tr>
</thead>
</table>
| **Moderate asthma exacerbation**          | Subject experienced one or more of the 4 following criteria and it led to change in treatment:  
1. Nocturnal awakening(s) due to asthma requiring short-acting β2-agonist (SABA) for two consecutive nights or increase of ≥ 0.75 from baseline in daily symptom score on two consecutive days  
2. Increase from baseline in occasions of SABA use on two consecutive days (minimum increase: 4 puffs/day)  
3. ≥ 20% decrease in PEF from baseline on at least two consecutive mornings/evenings or ≥ 20% decrease in FEV₁ from baseline  
4. Visit to the emergency room / trial site for asthma treatment not requiring systemic corticosteroids |
| **Severe asthma exacerbation**            | Subject experienced at least one of the following criteria:  
1. Need for systemic corticosteroids for ≥ 3 days  
2. Emergency room visit requiring systemic corticosteroids or hospitalisation for ≥ 12 h |

Table 2. Efficacy outcomes for ACARIZAX® Phase III clinical trial MT-04 (MITRA)

<table>
<thead>
<tr>
<th></th>
<th>6 SQ-HDM vs placebo</th>
<th>12 SQ-HDM vs placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Time to first asthma exacerbation (FAS-MI)</strong>&lt;sup&gt;a,b&lt;/sup&gt; (n=834)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR [CI 95%]</td>
<td>0.72 [0.52, 0.99]</td>
<td>0.69 [0.50, 0.96]</td>
</tr>
<tr>
<td>% risk reduction&lt;sup&gt;a&lt;/sup&gt;</td>
<td>28%</td>
<td>31%</td>
</tr>
<tr>
<td>p-value</td>
<td>0.0447</td>
<td>0.0271</td>
</tr>
<tr>
<td><strong>Time to first asthma exacerbation (FAS)</strong>&lt;sup&gt;c&lt;/sup&gt; (n=742)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR [CI 95%]</td>
<td>0.69 [0.49, 0.96]</td>
<td>0.66 [0.47, 0.93]</td>
</tr>
<tr>
<td>% risk reduction&lt;sup&gt;c&lt;/sup&gt;</td>
<td>31%</td>
<td>34%</td>
</tr>
<tr>
<td>p-value</td>
<td>0.0238</td>
<td>0.0170</td>
</tr>
</tbody>
</table>

**Pre-defined analyses of components of the primary endpoint**

|                        |                      |                       |
| **Time to first asthma exacerbation with deterioration in asthma symptoms**<sup>c,d</sup> |                      |                       |
| HR [CI 95%]            | 0.72 [0.49, 1.07]    | 0.64 [0.42; 0.96]     |
| % risk reduction<sup>c</sup> | 28%                  | 36%                   |
| p-value                | 0.1069               | 0.0312                |
| **Time to first asthma exacerbation with increased SABA use**<sup>e</sup> |                      |                       |
| HR [CI 95%]            | 0.62 [0.36, 1.07]    | 0.52 [0.29; 0.94]     |
| % risk reduction<sup>e</sup> | 38%                  | 48%                   |
| p-value                | 0.0857               | 0.0293                |
| **Time to first asthma exacerbation with deterioration in lung function**<sup>e</sup> |                      |                       |
| HR [CI 95%]            | 0.60 [0.38, 0.95]    | 0.58 [0.36; 0.93]     |
| % risk reduction<sup>e</sup> | 40%                  | 42%                   |
| p-value                | 0.0297               | 0.0221                |
| **Time to first severe** |                      |                       |
| HR [CI 95%]            | 0.79 [0.40, 1.55]    | 0.49 [0.23; 1.08]     |
| % risk reduction<sup>e</sup> | 21%                  | 51%                   |
| p-value                | 0.4887               | 0.076                 |
exacerbation

| a: Estimated by hazard ratio (HR). Clinical relevance pre-specified as HR ≤ 0.70. |
| b: Full analysis set (FAS) with multiple imputations (FAS-MI) - analysis treats all subjects who discontinued from the trial prior to ICS reduction as placebo subjects. |
| c: Full analysis set (FAS) – analysis uses all available data used to its full extent, i.e. subjects who provided data during the efficacy assessment period. |
| d: Criterion included daily asthma symptom score and nocturnal awakenings requiring SABA |

**Figure 1. Kaplan-Meier plot of the probability of having a first moderate or severe asthma exacerbation (FAS)**

Time=0 equals the time of ICS reduction, time=90 is the approximate time of ICS withdrawal. The numbers at the bottom are the numbers of subjects still at risk in each treatment group at each time point.

**Allergic rhinitis**

The efficacy and safety of ACARIZAX® in adults with persistent moderate-to-severe HDM-allergic rhinitis despite use of symptom-relieving medication has been investigated in a Phase III randomised, double-blind, placebo-controlled, parallel-group, multicentre study (MT-06, MERIT) (n=992). The definition of persistent and moderate to severe allergic rhinitis is provided in Table 3.

**Table 3: Definitions of persistent and moderate to severe allergic rhinitis (clinical trial MT-06)**

<table>
<thead>
<tr>
<th>Classification of allergic rhinitis</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Persistent                        | Subject experienced at least one of the following criteria:  
  - Clinical history of moderate to severe HDM allergic rhinitis for at least 1 year prior to the trial  
  - Moderate to severe HDM allergic rhinitis symptoms during the baseline period defined as a daily total rhinitis score of at least 6 or a score of at least 5 with one symptom being severe, during at least 8 days of the 15 days baseline period  
  - Use of symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the 15 days baseline period |
Moderate to severe

Subject experienced at least one or more of the following items:
- Use of symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the 15 days baseline period
- Sleep disturbance
- Impairment of daily activities, leisure and/or sport
- Impairment of school or work

Subjects were randomised to receive ACARIZAX® 12 SQ-HDM, 6 SQ-HDM or placebo once daily for 12 months. Use of nasal steroids (budesonide 64 mcg/dose), oral antihistamines (desloratadine tablets, 5 mg), and antihistamine eye drops (azelastine 0.05%) was permitted as needed.

The primary endpoint was the average daily total combined rhinitis score (TCRS) evaluated during the last 8 weeks of treatment. The TCRS was the sum of the rhinitis symptoms score and the rhinitis medication score (maximum total possible score 24). The rhinitis symptoms score evaluated 4 nasal symptoms (runny nose, blocked nose, itching nose, sneezing) daily on a 0-3 scale (no, mild, moderate, severe symptoms) for a maximum total possible score of 12. The rhinitis medication score was the sum of the score for nasal steroid intake (2 points per puff, max. 4 puffs/day) and oral antihistamine intake (4 points/tablet, max. 1 tablet/day) for a maximum total possible score of 12.

The results for the primary endpoint are summarised in Table 4. Both ACARIZAX® 12 and 6 SQ-HDM demonstrated a statistically significant reduction in TCRS compared to placebo. The results for both ACARIZAX® 12 and 6 SQ-HDM also met the pre-specified criterion for clinical relevance compared to placebo (i.e. TCRS ≥ 1) commencing from 14 weeks of treatment and continuing for the duration of the trial.

Table 4. Efficacy outcomes for ACARIZAX® Phase III clinical trial MT-06 (MERIT)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Adjusted mean TCRS [95% CI]</th>
<th>Absolute difference to placebo [95% CI]</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAS-MIa (n=992)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>6.81 [6.48, 7.13]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6 SQ-HDM</td>
<td>5.74 [5.42, 6.05]</td>
<td>1.07 [0.34; 1.80]</td>
<td>0.004</td>
</tr>
<tr>
<td>12 SQ-HDM</td>
<td>5.71 [5.40, 6.02]</td>
<td>1.09 [0.35; 1.84]</td>
<td>0.004</td>
</tr>
<tr>
<td>FAS with observationsb (n=879)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>6.76 [5.94, 7.63]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6 SQ-HDM</td>
<td>5.58 [4.81, 6.40]</td>
<td>1.18 [0.45; 1.91]</td>
<td>0.002</td>
</tr>
<tr>
<td>12 SQ-HDM</td>
<td>5.53 [4.77, 6.35]</td>
<td>1.22 [0.49; 1.96]</td>
<td>0.001</td>
</tr>
</tbody>
</table>

a: Full analysis set with multiple imputations (FAS-MI) - analysis treats all subjects who discontinued from the trial prior to the efficacy evaluation period as placebo subjects
b: Full analysis set (FAS) with observations – all randomised subjects with observations of the endpoint of interest
c: Clinical relevance pre-specified as absolute difference in TCRS between active and placebo ≥ 1

Paediatric population

The SQ HDM SLIT-tablet has been administered to 212 subjects between 5 and 17 yrs of age in Phase I/II/III clinical trials. In these trials, all subjects had HDM allergic asthma and/or HDM allergic rhinitis. No overall differences in safety, tolerability and/or effectiveness were observed between subjects aged 5-17 years compared to subjects ≥ 18 years of age. However, the data are currently not sufficient to support
use in children. ACARIZAX® is not recommended for use in children below 18 years of age. See PRECAUTIONS and DOSAGE AND ADMINISTRATION.

Table 5 summarises the efficacy outcomes from paediatric subjects aged 14-17 years of age (n=39) and adults ≥ 18 years of age (n=565) from the supportive Phase II/III clinical trial MT-02 (n=604). Overall, 67% of subjects 14-17 years of age administered 6 SQ-HDM once daily for 1 year demonstrated reduction in ICS use compared to 45% of subjects administered placebo.

Table 5. Efficacy outcomes from Phase II/III clinical trial MT-02 (FAS)

<table>
<thead>
<tr>
<th>Subjects 14-17 years of age</th>
<th>Subjects ≥ 18 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (N=11)</td>
</tr>
<tr>
<td>Mean ICS use at baseline (µg/day)</td>
<td>409</td>
</tr>
<tr>
<td>Mean ICS use after 12 months treatment (year 1) (µg/day)</td>
<td>191</td>
</tr>
<tr>
<td>Mean % reduction of ICS</td>
<td>36%</td>
</tr>
<tr>
<td>Percentage of subjects with a decrease in ICS at year 1</td>
<td>45%</td>
</tr>
</tbody>
</table>

FAS: Full analysis set
a: 1 SQ-HDM and 3 SQ-HDM doses did not show statistically significant difference from placebo in the primary efficacy analysis.
b: The 6 SQ-HDM dose showed a statistically significant difference from placebo in the primary efficacy analysis.
c: Prior to treatment with HDM allergen extract, subjects were switched from their normal ICS treatment to inhaler treatment with budesonide. The dose of budesonide prescribed was equipotent to their normal dose of ICS. This was done in order to standardise the steroid treatment.

Of the 212 paediatric subjects administered the SQ HDM SLIT-tablet, 74 subjects received ACARIZAX® 12 SQ-HDM. Table 6 summarises the pooled safety data from clinical trials for paediatric subjects aged 5-17 years of age administered ACARIZAX®. The most common TEAEs included oral pruritus, throat irritation, oedema mouth and lip swelling (see Table 6). Similar TEAEs were also commonly reported for subjects ≥ 18 years of age (see ADVERSE EFFECTS).

Table 6. Most common TEAEs in paediatrics aged 5-17 years

<table>
<thead>
<tr>
<th>System organ class/preferred term</th>
<th>Paediatrics aged 5-17 years*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (N=83) n (%)</td>
</tr>
<tr>
<td>All events</td>
<td>45 (54%)</td>
</tr>
<tr>
<td>Oral Pruritus</td>
<td>9 (11%)</td>
</tr>
<tr>
<td>Throat irritation</td>
<td>4 (5%)</td>
</tr>
<tr>
<td>Lip swelling</td>
<td>NR</td>
</tr>
<tr>
<td>Oedema mouth</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR: not reported
a: Includes studies MT-03 and P008.

INDICATIONS

ACARIZAX® is indicated for the treatment of adults diagnosed with:
- house dust mite (HDM) allergic rhinitis not well controlled despite use of symptom relieving medication or
- HDM allergic asthma not well controlled by inhaled corticosteroids and associated with HDM allergic rhinitis.

Patients’ asthma status should be carefully evaluated before the initiation of treatment.

CONTRAINDICATIONS

ACARIZAX® is contraindicated in patients:
- with a known hypersensitivity to any of the excipients
- with FEV₁ <70% of predicted value (after adequate pharmacological treatment) at initiation of treatment
- who have experienced a severe asthma exacerbation within the last 3 months
- with asthma and experiencing an acute respiratory tract infection, initiation of ACARIZAX® treatment should be postponed until the infection has resolved.
- with active or poorly controlled autoimmune diseases, immunodeficiencies, immunosuppression or malignant neoplastic disease
- with acute severe oral inflammation or oral wounds (see PRECAUTIONS).

PRECAUTIONS

Patients should be advised that ACARIZAX® is not intended to treat acute asthma exacerbations. In the event of an acute asthma exacerbation, a short-acting bronchodilator should be used. If short-acting bronchodilator treatment is ineffective or there is a need for more inhalations than usual, medical attention must be sought.

Abrupt discontinuation of asthma controller medication after initiation of ACARIZAX® treatment is not recommended. Decreases in asthma controller medication should be gradual and performed under medical supervision.

Asthma is a known risk factor for severe systemic allergic reactions.

Patients must be advised to seek urgent medical attention should their asthma deteriorate suddenly.

When treated with ACARIZAX® the patient is exposed to the allergen that causes the allergic symptoms. Therefore local allergic reactions are to be expected during the treatment period (see ADVERSE EFFECTS). The use of anti-allergic medication (e.g. antihistamines) should be considered for any potential significant local adverse reactions to ACARIZAX®.

Treatment with ACARIZAX® should be discontinued immediately and urgent medical attention sought in cases of severe systemic allergic reactions, severe asthma exacerbation, angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, hypotension or feeling of fullness in the throat.
Although side effects are more likely to occur within the first two months of commencing ACARIZAX®, they can occur at any time throughout the therapy.

Initiation of ACARIZAX® in patients who have previously had a systemic allergic reaction to subcutaneous HDM immunotherapy should be carefully considered, and measures to treat any potential adverse reactions should be available.

Severe systemic allergic reactions may be treated with adrenaline. The effects of adrenaline may be potentiated in patients treated with tricyclic antidepressants, mono amino oxidase inhibitors (MAOIs) and/or COMT inhibitors with possible fatal consequences. The effects of adrenaline may be reduced in patients treated with beta-blockers.

Patients with cardiac disease who suffer a systemic allergic reaction may be at increased risk of a severe systemic allergic reaction. Clinical experience with the use of ACARIZAX® in patients with cardiac disease is limited.

This should be taken into consideration prior to initiating allergy immunotherapy.

In patients with severe oral inflammation (e.g. oral lichen planus, mouth ulcers or thrush), oral wounds or following oral surgery, including dental extraction, or following tooth loss, initiation of ACARIZAX® treatment should be postponed and any ongoing treatment should be temporarily interrupted to allow healing of the oral cavity (see DOSAGE AND ADMINISTRATION).

Isolated cases of eosinophilic oesophagitis have been reported in ACARIZAX® clinical trials. Initiation of ACARIZAX® in patients with known eosinophilic oesophagitis should be carefully considered, and the possibility of exacerbating existing disease should be assessed. In patients with severe or persisting gastro-esophageal symptoms such as dysphagia, abdominal pain or dyspepsia, ACARIZAX® should be interrupted and medical attention must be sought.

Limited data is available on treatment with allergy immunotherapy in patients with autoimmune diseases in remission. ACARIZAX® should therefore be prescribed with caution in these patients.

**Effects on fertility**

There is no data available regarding fertility and use of ACARIZAX®. While dedicated fertility studies have not been conducted, histopathological assessment performed as part of the 26 week repeat dose toxicity study in mice showed no effects on the reproductive organs attributable to ACARIZAX®.

**Use in pregnancy (Category B2)**

There is no data available regarding use of ACARIZAX® during pregnancy. No adverse effects were observed in an embryo-fetal development study in mice with doses approximately 680 times greater than clinical doses.
Treatment with ACARIZAX® should not be initiated during pregnancy. If pregnancy occurs during treatment, the treatment may continue after evaluation of the general condition (including lung function) of the patient and reactions to previous administration of ACARIZAX®.

Close supervision during pregnancy is recommended for patients with pre-existing asthma.

**Use in lactation**

No clinical data are available for the use of ACARIZAX® during lactation. Studies in animals to investigate excretion of ACARIZAX® into milk were not conducted. No effects on the breastfed infants are anticipated.

Initiation of allergy immunotherapy while breast feeding is not recommended. However if breast feeding is required during treatment, patients should be closely monitored.

**Paediatric use**

ACARIZAX® is not recommended for use in children below 18 years of age. See also **CLINICAL TRIALS**.

**Use in the elderly**

Special studies in the geriatric population have not been performed; however, ACARIZAX® has been administered to 13 subjects ≥ 65 years of age. No overall differences in safety and effectiveness were observed between these subjects and younger subjects.

**Genotoxicity**

Results from genotoxicity testing indicate that ACARIZAX® does not pose any genotoxic risk to humans.

**Carcinogenicity**

Dedicated carcinogenicity studies with the HDM tablet have not been conducted.

**Effect on laboratory tests**

ACARIZAX® has no effect on laboratory tests.

**Effects on ability to drive and use machines**

Treatment with ACARIZAX® has no or negligible influence on the ability to drive or use machines.

**INTERACTIONS WITH OTHER MEDICINES**

No interaction trials have been conducted in humans and no potential drug interactions have been identified from any source.

**ADVERSE EFFECTS**
Treatment emergent adverse events in adults in the double-blind Phase II/III studies

In the pooled Phase II/III ACARIZAX® studies, the percentage of adult subjects administered ACARIZAX® with at least 1 TEAE was 68.9%. This was higher when compared with the placebo group (54.4%).

The majority of subjects in all treatment groups in the pooled all Phase II/III ACARIZAX® studies experienced TEAEs that were mild to moderate in intensity.

The most frequently reported TEAEs (defined as those occurring in ≥ 5% of subjects in any active group) are summarised by system organ class (SOC) in Table8.

Table 7. TEAEs in at least 5% of adult subjects in the ACARIZAX® Phase II/III studies (safety population)

<table>
<thead>
<tr>
<th>System organ class/preferred term</th>
<th>Placebo (N=788) n (%)</th>
<th>ACARIZAX® 12 SQ-HDM (N=642) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear pruritus</td>
<td>3 (&lt;1%)</td>
<td>31 (5%)</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oedema mouth</td>
<td>1 (&lt;1%)</td>
<td>67 (10%)</td>
</tr>
<tr>
<td>Oral pruritus</td>
<td>21 (3%)</td>
<td>127 (20%)</td>
</tr>
<tr>
<td>Paraesthesia oral</td>
<td>2 (&lt;1%)</td>
<td>35 (5%)</td>
</tr>
<tr>
<td>Tongue pruritus</td>
<td>7 (&lt;1%)</td>
<td>31 (5%)</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>32 (4%)</td>
<td>30 (5%)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>120 (15%)</td>
<td>103 (16%)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>35 (4%)</td>
<td>39 (6%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>38 (5%)</td>
<td>30 (5%)</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>37 (5%)</td>
<td>31 (5%)</td>
</tr>
<tr>
<td>Throat irritation</td>
<td>19 (2%)</td>
<td>98 (15%)</td>
</tr>
</tbody>
</table>

The most common TEAEs included oral pruritus, nasopharyngitis, throat irritation, and oedema mouth (reported by 20%, 16%, 15% and 10% of subjects (Table5). In the pooled Phase II/III studies, time to onset from first administration for oral pruritus, throat irritation and oedema mouth was typically fast (median onset 2 minutes, 2 minutes and 1 minute after first administration respectively). See also PRECAUTIONS.

Adverse reactions reported in clinical trials with < 5% frequencies are listed below.

Adverse reactions are divided into groups according to the MedDRA convention frequencies: Very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Infections and infestations
Common: Laryngitis, rhinitis, sinusitis

Nervous system disorders
Uncommon: Dizziness, dysgeusia

Eye disorders
Common: Eye pruritus

Respiratory, thoracic and mediastinal disorders
Common: Dysphonia, dyspnoea, oropharyngeal pain, pharyngeal oedema
Uncommon: Laryngeal oedema, nasal congestion, nasal discomfort, rhinorrhea, sneezing, throat tightness

Gastrointestinal disorders
Common: Abdominal pain, diarrhea, dry mouth, dysphagia, dyspepsia, glossodynia, lip oedema, lip pruritus, nausea, oral discomfort, stomatitis, tongue oedema
Uncommon: Glossitis, mouth ulceration, oesophageal irritation, oral mucosal blistering, oral mucosal erythema, vomiting

General disorders and administration site conditions
Common: Chest discomfort
Uncommon: Fatigue, malaise, sensation of foreign body

Skin and subcutaneous tissue disorders
Uncommon: Pruritus

Post marketing experience
To date, there is limited post marketing data available for ACARIZAX®.

Cases of systemic allergic reactions have been reported for a corresponding sublingual tablet product for grass pollen allergy and are considered a class effect. Medical supervision at first oral lyophilisate intake is therefore recommended (see DOSAGE AND ADMINISTRATION).

DOSAGE AND ADMINISTRATION

Treatment with ACARIZAX® should be initiated by a clinician with experience in treatment of allergies. Patients should have a confirmed clinical history and a positive test of house dust mite sensitisation (specific IgE and/or skin prick test) prior to treatment.

The recommended dose for adults is one oral lyophilisate (12 SQ-HDM) daily.
It is recommended that the first oral lyophilisate is taken under medical supervision and that the patient is monitored for 30 minutes, to enable discussion and possible treatment of any immediate side effects. See also PRECAUTIONS.

The oral lyophilisate should be taken with dry fingers from the blister unit immediately after opening the blister and placed under the tongue, where it will disperse. Swallowing should be avoided for approximately 1 minute. Food and beverage should not be consumed for the following 5 minutes.

Onset of the clinical effect is to be expected 8-14 weeks after initiation. Limited efficacy data is available for 13-18 months of treatment. No efficacy data is available for >18 months of treatment. If no improvement is observed during the first year of treatment with ACARIZAX® there is no indication for continuing treatment.

ACARIZAX® is not recommended for use in children below 18 years of age due to insufficient data on safety and efficacy in this population. See also CLINICAL TRIALS.

If treatment with ACARIZAX® is interrupted for a period of up to 7 days, treatment can be resumed by the patient. If treatment is interrupted for more than 7 days, it is recommended to seek medical advice before continuing treatment.

Refer to treatment guidelines for recommendations on the duration of patient treatment.

OVERDOSAGE

There have been no cases of overdosage reported.

If doses higher than the recommended daily dose are taken, the risk of undesirable effects, including systemic side effects or severe local adverse reactions, may increase. In case of severe reaction such as angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, or feeling of fullness in the throat, immediate medical evaluation is needed.

In the event of an overdose, the adverse effects should be treated symptomatically.

Contact the Poisons Information Centre on 131 126 for advice on overdosage management.

PRESENTATION AND STORAGE CONDITIONS

ACARIZAX® 12 SQ-HDM is supplied as white to off-white freeze-dried debossed oral lyophilisate tablets.

Packs contain 10, 30 and 90 oral lyophilisate tablets supplied in aluminium blister foils.
Not all pack sizes may be available.

ACARIZAX® 12 SQ-HDM oral lyophilisate has a shelf-life of 36 months when stored below 25°C. Protect from light.

NAME AND ADDRESS OF SPONSOR

Seqirus Pty Ltd ABN: 26 160 735 035
63 Poplar Road
Parkville VIC 3052

POISON SCHEDULE OF THE MEDICINE

Prescription Only Medicine, S4

Date of first inclusion in the Australian Register of Therapeutic Goods:
01 August 2016

Date of most recent amendment:
N/A

ACARIZAX® is a registered trademark of ALK-Abelló A/S, used under licence.